TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24123804
Drug: Platelet counts
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet counts < 60 × 10(9) /L on POD5
Study: 24126237
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) with risedronate
Study: 24126237
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) without bisphosphonate therapy
Study: 24127452
Drug: Pidilizumab (anti-PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidilizumab (anti-PD-1 monoclonal antibody), administered as three doses beginning 1 to 3 months after AHSCT.
Study: 24128118
Drug: Conventional drug-susceptibility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug-susceptibility testing (DST)
Study: 24128336
Drug: Low vitamin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vitamin A status (serum retinol <1·05 μmol/l)
Study: 24128336
Drug: Middle vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle vitamin A tertile (1·056-1·298 μmol/l)
Study: 24128669
Drug: BMS-626529 (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-626529 (an attachment inhibitor administered as the prodrug BMS-663068)
Study: 24130489
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) for 24 weeks
Study: 24131779
Drug: Dinaciclib (0.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib (0.33 mg/m2 to 14 mg/m2, 2-hour intravenous infusion once weekly for 3 weeks)
Study: 24131779
Drug: Dinaciclib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib at RP2D (12 mg/m2)
Study: 24131779
Drug: Dinaciclib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib (various doses)
Study: 24131779
Drug: Dinaciclib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib (all doses)
Study: 24132613
Drug: Liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.2 mg daily
Study: 24134221
Drug: HIV-1-specific antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1-specific antibody responses to transmembrane glycoprotein (TM) and reverse transcriptase (RT)
Study: 24134221
Drug: HIV-1-specific antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1-specific antibody responses to surface glycoprotein (SU), capsid (CA), matrix (MA), and integrase (IN)
Study: 24134221
Drug: HIV-1-specific antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1-specific antibody responses to capsid (CA), matrix (MA), and integrase (IN)
Study: 24134221
Drug: HIV-1-specific antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1-specific antibody responses to capsid (CA) and integrase (IN)
Study: 24138944
Drug: Decitabine (DAC)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine (DAC) 20mg/m² intravenously daily for 5 days followed by rapamycin at doses of 2 mg, 4 mg, and 6 mg/day from day 6 to day 25
Study: 24139613
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy consisting of 2 cycles of cisplatin and etoposide combined with 45 Gy of thoracic radiotherapy
Study: 24140121
Drug: ApoCell (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApoCell (higher doses)
Study: 24144215
Drug: Dipyrone 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 15 mg/kg
Study: 24144643
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of elevated serum free light chain, M-spike, and GEP70 risk score
Study: 24145340
Drug: Dose-escalated hypofractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated hypofractionated radiotherapy (RT) with total doses ranging from 57 to 85.5 Gy in 25 daily fractions over 5 weeks using intensity-modulated radiotherapy.
Study: 24145340
Drug: Dose-escalated hypofractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated hypofractionated radiotherapy (RT)
Study: 24145345
Drug: Nivolumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab with vaccine
Study: 24145345
Drug: Nivolumab at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab at 3 mg/kg with or without peptide vaccine
Study: 24145880
Drug: Ritonavir-boosted atazanavir
Normalized name: atazanavir and ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted atazanavir (ATVr) 300/100 mg every 24 hours
Study: 24145880
Drug: Unboosted atazanavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unboosted atazanavir (200 mg every 12 hours)
Study: 24145879
Drug: Raltegravir as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir as a film-coated tablet 400 mg twice daily (6 to <19 years, and ≥ 25 kg)
Study: 24145879
Drug: Raltegravir as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir as a chewable tablet 6 mg/kg (maximum dose 300 mg) twice daily (2 to <12 years)
Study: 24145879
Drug: Raltegravir (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (both formulations)
Study: 24146220
Drug: Panitumumab (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (9 mg/kg) + Gemcitabine (1000 mg/m(2)) + Irinotecan (100 mg/m(2))
Study: 24148552
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg once daily (single dose on day 1 and multiple doses on days 4-10)
Study: 24151550
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol ester (STAEST) in soymilk-based minidrink (2.7 g/d, 65 mL/d)
Study: 24152880
Drug: Specialised palliative
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialised palliative care (SPC) plus standard treatment
Study: 24153347
Drug: Cyclooxygenase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclooxygenase inhibitors (NSAIDs) >6 months
Study: 24155157
Drug: Tigecycline (100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (100-mg infusion followed by two 50-mg infusions, each administered over 30 minutes)
Study: 24156629
Drug: Community health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community health coach integration, home blood pressure monitoring, standardized care delivery processes, and improved medication adherence
Study: 24157897
Drug: Paracetamol-Morphine Combination
Normalized name: morphine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol-Morphine Combination
Study: 24157897
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and Morphine Combination
Study: 24158411
Drug: Trastuzumab, lapatinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab, lapatinib, and bevacizumab (trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance dose, intravenously every 3 weeks; lapatinib 1250 mg daily; bevacizumab 15 mg/kg intravenously every 3 weeks)
Study: 24159060
Drug: tPA alone
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA alone (standard-dose intravenous)
Study: 24161160
Drug: Rilpivirine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine (25 mg once daily) co-administered with ethinylestradiol (35 μg)/norethindrone (1 mg)
Study: 24161161
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of tocilizumab (TCZ)
Study: 24161161
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OC; norethindrone (NE) and ethinyl estradiol (EE))
Study: 24161161
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OC) with or without a single dose of TCZ
Study: 24165173
Drug: Anidulafungin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidulafungin (100 mg once daily after a loading dose of 200 mg on the first day)
Study: 24166890
Drug: Continued medical
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued medical therapy (CMT) for a mean of 7.1 months
Study: 24168522
Drug: EEG-neurofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEG-neurofeedback treatment
Study: 24168522
Drug: Placebo-neurofeedback treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-neurofeedback treatment
Study: 24170610
Drug: GDC-0449 150
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-0449 150 mg/day (days 1-28, 28-day cycle)
Study: 24171147
Drug: Naltrexone 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 32 mg/d and Bupropion 360 mg/d (NB32) with dietary and behavioral counseling
Study: 24171941
Drug: Combined positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined positive imagery CBM and internet cognitive behavioural therapy (iCBT)
Study: 24172304
Drug: Baseline characteristics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline characteristics (plasma insulin, IL-6, adipose tissue inflammation, Lactobacillus/Leuconostoc/Pediococcus numbers)
Study: 24173967
Drug: Dasatinib (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (70 mg daily) in combination with capecitabine (850 mg/m² twice daily, days 1-14), oxaliplatin (130 mg/m² on day 1), and bevacizumab (7.5 mg/kg on day 1), every 3 weeks
Study: 24173967
Drug: Dasatinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (50 mg bid)
Study: 24173967
Drug: Dasatinib (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (70 mg daily)
Study: 24177180
Drug: Anti-OX40 monoclonal
Normalized name: Agonistic anti-OX40 monoclonal antibody MEDI6469
DrugBank: MEDI-6469 (DB15306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-OX40 monoclonal antibody (mAb)
Study: 24177377
Drug: Fluticasone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone therapy
Study: 24184736
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks until week 52
Study: 24188875
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg recombinant hCG (r-hCG)
Study: 24193798
Drug: RP-1127 (glyburide
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP-1127 (glyburide for injection) at a dose of 3 mg/d
Study: 24195547
Drug: Biopsies with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopsies with antibody-mediated rejection or acute tubular necrosis
Study: 24196401
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment during pregnancy
Study: 24200517
Drug: Automated text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated text message based weight loss program (3-5 text messages daily for 8 weeks, including printed materials and weekly counseling calls)
Study: 24201857
Drug: Single-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose IV sildenafil (0.25, 0.35, or 0.45 mg/kg over 20 min)
Study: 24211066
Drug: Intramyocardial injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injection of autologous bone-marrow derived mesenchymal stromal cells (BMMSCs)
Study: 24214905
Drug: Cefazolin 2
Normalized name: cefazolin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 2 g intravenously before surgery
Study: 24218035
Drug: Sorafenib (So)
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib (So) treatment
Study: 24218513
Drug: Imiquimod ointment
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod ointment and subcutaneous vaccinations (100 μg IDO5 peptide, sequence ALLEIASCL, formulated in 900 μL Montanide)
Study: 24220277
Drug: CBT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBT intervention with weekly therapist contact
Study: 24220703
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg mifepristone vaginally daily for 3 months
Study: 24221839
Drug: CVD-medication nonadherence
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD-medication nonadherence
Study: 24223036
Drug: Integrated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive behavioral therapy
Study: 24224560
Drug: Recombinant viruslike
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant viruslike particle influenza A (H7N9) vaccine
Study: 24225051
Drug: 4-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day course of corticosteroid treatment
Study: 24225051
Drug: No corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No corticosteroid treatment
Study: 24228627
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of short cervix and IL-8
Study: 24229439
Drug: Subcutaneous-allergen-specific-immunotherapy (SCIT)
Normalized name: Pacific halibut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous-allergen-specific-immunotherapy (SCIT)
Study: 24232700
Drug: Intrabronchial valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrabronchial valve treatment
Study: 24234516
Drug: p53 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: p53 antibody testing in patients with thyroid cancer
Study: 24234516
Drug: p53 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: p53 antibody testing in healthy subjects
Study: 24234516
Drug: p53 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: p53 antibody testing in dedifferentiated patients with high Tg level and negative radioiodine scan
Study: 24241210
Drug: Flavopiridol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavopiridol (30 mg/m² bolus, 30 mg/m² continuous infusion to 50 mg/m² bolus, and 50 mg/m² continuous infusion)
Study: 24242861
Drug: AS1411 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS1411 (40 mg/kg/day by continuous intravenous infusion on days 1-4 of a 28-day cycle, for two cycles)
Study: 24246506
Drug: Low-dose paclitaxel
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose paclitaxel (15 mg/m² IV) with timed thoracic radiotherapy (TTR) (total 55 Gy) followed by adjuvant chemotherapy (carboplatin AUC 5 on day 1, gemcitabine 1000 mg/m² on days 1 and 8, every 21 days for 4 cycles)
Study: 24246506
Drug: Low-dose paclitaxel
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose paclitaxel with concurrent TTR
Study: 24246704
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg orally per day, with dose escalation by 25mg every two weeks until grade 2/tolerable rash or other dose limiting toxicity developed.
Study: 24246704
Drug: Erlotinib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib dose escalation to the development of grade 2 skin rash.
Study: 24246704
Drug: Comparison to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison to first-line chemotherapy.
Study: 24246789
Drug: Caregiver Pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver Pain Medicine Questionnaire
Study: 24247327
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficiency (<75 nmol/L)
Study: 24251951
Drug: Insulin-resistant group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-resistant group (HOMA-IR >4)
Study: 24251951
Drug: Insulin-sensitive group
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-sensitive group (HOMA-IR ≤ 4)
Study: 24252402
Drug: MK-2206 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 (60 mg QOD schedule)
Study: 24252402
Drug: MK-2206 (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 (135 mg QW schedule)
Study: 24252402
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MK-2206 and trastuzumab
Study: 24253138
Drug: Extended heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended heparin prophylaxis (4 weeks)
Study: 24253138
Drug: Short heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short heparin prophylaxis (1 week)
Study: 24254708
Drug: Drug-eluting absorbable
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting absorbable metal scaffold
Study: 24255769
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent.
Study: 24256329
Drug: Low-dose rate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rate brachytherapy
Study: 24257514
Drug: Raw vegetable
Normalized name: raw vegetable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw vegetable intake (68 g per 1000 kcal)
Study: 24257514
Drug: Cooked vegetable
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked vegetable intake (92 g per 1000 kcal)
Study: 24258465
Drug: E7107 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7107 at 5.7 mg/m(2)
Study: 24258465
Drug: E7107 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7107 at 4.3 mg/m(2)
Study: 24258465
Drug: E7107 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7107 (various doses)
Study: 24258465
Drug: E7107 (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7107 (3.2 mg/m(2) and 4.3 mg/m(2))
Study: 24261605
Drug: Acetylcholinesterase inhibitors
Normalized name: acetylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholinesterase inhibitors (CEIs)
Study: 24261605
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anti-dementia drugs)
Study: 24261996
Drug: BPZE1 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPZE1 administered intranasally before RSV infection
Study: 24261996
Drug: BPZE1 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPZE1 administered neonatally
Study: 24261996
Drug: Anti-IL-17 antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-IL-17 antibodies
Study: 24262016
Drug: Opioid administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid administration specifically for the procedure
Study: 24263064
Drug: gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gefitinib 250 mg day(-1) until progression
Study: 24263462
Drug: Velaglucerase alfa
Normalized name: Velaglucerase alfa
DrugBank: Velaglucerase alfa (DB06720)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Velaglucerase alfa (60 U/kg for treatment-naïve patients; 15-60 U/kg for previously treated patients)
Study: 24264034
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac 0.45%, 4 times daily, for 3 days before surgery
Study: 24264034
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac 0.45%
Study: 24265670
Drug: Rapamycin (preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin (preventive treatment for 25 days starting one day before myosin immunization)
Study: 24265670
Drug: Rapamycin (curative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin (curative treatment for 10 days following the last myosin immunization)
Study: 24267310
Drug: Novel medical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel medical therapies for pulmonary arterial hypertension
Study: 24267809
Drug: Bupropion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion therapy
Study: 24270505
Drug: β blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: β blockers started during hospital admission for myocardial infarction
Study: 24270505
Drug: Patients already
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients already taking β blockers before myocardial infarction
Study: 24270505
Drug: β blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: β blockers started during hospital admission for myocardial infarction (follow-up from discharge)
Study: 24273046
Drug: chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy alone (HER2-negative disease)
Study: 24273135
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal doxorubicin (40 mg/m² on day 1), vincristine (2 mg on day 1), dexamethasone (40 mg on days 1-4), lenalidomide (10 mg on days 1-21 of every 28-day cycle) followed by lenalidomide maintenance therapy.
Study: 24273135
Drug: Lenalidomide maintenance
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide maintenance therapy (at last tolerated dose until progression, with or without 50 mg prednisone every other day).
Study: 24273135
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy (combination of drugs mentioned).
Study: 24273135
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (combination of drugs mentioned).
Study: 24273151
Drug: Ciclopirox olamine
Normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox olamine 10 mg/m² once daily